Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe

Reacquiring rights to omaveloxolone from AbbVie looks great business

 
• By Kevin Grogan
  
Chart_Sketch
Reata stock is on the up on Friedreich’s ataxia data • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip